Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

NCT00219219 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2003
Completion date
October 31, 2006
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer